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The Lyme disease spirochete, Borrelia burgdorferi, infects multiple tissues, such as the heart, joint, skin, and
nervous system and has been shown to recognize heparan sulfate and dermatan sulfate proteoglycans. In this
study, we examined the contribution of different classes of proteoglycans to the attachment of the infectious B.
burgdorferi strain N40 to several immortalized cell lines and primary cultured cells, including endothelial cells
and brain cells. Bacterial attachment was inhibited by exogenous proteoglycans or by treatment of host cells
with inhibitors of proteoglycan synthesis or sulfation, indicating that proteoglycans play a critical role in
bacterial binding to diverse cell types. Binding to primary bovine capillary endothelial cells or a human
endothelial cell line was also inhibited by digestion with heparinase or heparitinase but not with chondroiti-
nase ABC. In contrast, binding to glial cell-enriched brain cell cultures or to a neuronal cell line was inhibited
by all three lyases. Binding of strain N40 to immobilized heparin could be completely inhibited by dermatan
sulfate, and conversely, binding to dermatan sulfate could be completely blocked by heparin. As measured by
50% inhibitory dose, heparin was a better inhibitor of binding than dermatan sulfate, regardless of whether the
substrate was heparin or dermatan sulfate. These results are consistent with the hypotheses that the species
of proteoglycans recognized by B. burgdorferi vary with cell type and that bacterial recognition of different
proteoglycans is mediated by the same bacterial molecule(s).
Lyme disease is a chronic, multisystemic infection caused by
the tick-borne spirochete Borrelia burgdorferi (40). The spiro-
chete initially establishes an infection at the site of the tick
bite and then migrates through the skin, resulting in the char-
acteristic expanding rash, erythema migrans. As the infection
progresses, the bacterium can spread via the bloodstream to
multiple sites, such as the joints, heart, skin, or nervous system.
During this phase of the infection, Lyme disease patients may
experience arthralgia, carditis, secondary erythema migrans
lesions, or neurologic manifestations such as meningitis, cra-
nial neuritis, or radiculoneuritis (40). Chronic infection may be
established in at least some of these tissues, as reflected by the
late manifestations of Lyme disease, which include arthritis
and a variety of neurological syndromes, such as encephalop-
athy or polyradiculoneuropathy (15, 25, 30). The spirochete
has been detected at a variety of these sites in Lyme disease
patients and infected laboratory animals (2, 34, 36). Thus,
although the pathophysiological mechanisms that result in the
manifestations of Lyme disease are not known in detail, infec-
tion of the affected tissues is likely to be the critical trigger.
Most bacterial pathogens are able to attach to host cells in
the target tissue, a step that is thought to contribute to the
establishment of an infectious niche at that site (3, 4). During
blood-borne dissemination from the site of tick inoculation,
B. burgdorferi must cross the endothelial cell barrier. Reflecting
this property, the spirochete has the ability to bind to and cross
confluent endothelial cell monolayers in vitro (7, 8, 32, 42).
Furthermore, the ability of B. burgdorferi to infect multiple
tissues may result in part from its ability to bind to many dif-
ferent cell types, including neuroglia (15, 16), epithelial cells
(44), fibroblasts (20, 28), lymphocytes (9), and platelets (5, 14).
B. burgdorferi binds to several classes of host cell molecules
expressed on the cell surface or in the extracellular matrix. For
example, the platelet-specific integrin aIIbb3 and two widely
expressed integrins, avb3 and a5b1, mediate bacterial attach-
ment to human cells (5, 6), while galactocerebroside promotes
attachment to Schwann cells (17). In addition, B. burgdorferi,
like many other microbial pathogens (39), binds to proteogly-
cans (19, 23, 29). Proteoglycans consist of core proteins co-
valently linked to long, linear, negatively charged disaccharide
repeats, termed glycosaminoglycans (27). They are widely ex-
presed and involved in diverse biological phenomena, such
as cell adhesion and migration, tumor metastasis, cell signaling,
and hemostasis. Depending on the composition of the di-
saccharide repeat and the overall extent of sulfation, glycos-
aminoglycans can be classified into several different species,
including heparin, heparan sulfate (formerly called heparitin
sulfate), chondroitin-4-sulfate (chondroitin sulfate A), chon-
droitin-6-sulfate (chondroitin sulfate C), dermatan sulfate
(chondroitin sulfate B), and keratan sulfate.
Because of their ubiquitous expression on the cell surface
and in the extracellular matrix, proteoglycans could mediate
spirochetal attachment to diverse tissues. B. burgdorferi attach-
ment to monkey kidney (Vero) cells is mediated by heparan
sulfate (29). The spirochete binds to heparan sulfate and der-
matan sulfate on human epithelial (HeLa) cells (23) and to
decorin, a dermatan sulfate/chondroitin sulfate proteoglycan
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associated with collagen fibrils (19). It is not clear whether
binding to different proteoglycans is mediated by the same
bacterial molecule(s) or by multiple molecules, each of which
recognizes a distinct subset of proteoglycans. The present study
was designed to investigate whether (i) the attachment of
B. burgdorferi to diverse cell types is mediated by glycosamino-
glycans, (ii) the host cell determinants of these interactions
exhibit cell type specificity, and (iii) binding to different classes
of glycosaminoglycans is likely to be mediated by the same
bacterial molecule(s).
MATERIALS AND METHODS
Bacteria and mammalian cells. B. burgdorferi N40, clone D10/E9, is an infec-
tious B. burgdorferi (sensu stricto) isolate (5). These strains were cultured in
MKP base medium (MKP-S) supplemented with human serum as described
previously (5, 37). Briefly, 100 ml of 103 CMRL medium, 3 g of neopeptone, 6 g
of HEPES, 0.7 g of sodium citrate, 3 g of glucose, 0.8 g sodium pyruvate, 0.8 g
of N-acetylglucosamine, and 2 g of sodium bicarbonate were added to 900 ml of
distilled H2O, and the pH was adjusted to 7.6. Then 200 ml of autoclaved 7%
gelatin, 35 ml of 35% bovine serum albumin (BSA) filtered through a 0.45-mm-
pore-size filter, and 70 ml of heat-inactivated human serum were added prior to
filtration through a 0.22-mm-pore-size filter. Radiolabeled B. burgdorferi was
prepared by growth in modified MKP medium supplemented with 100 mCi of
[35S]methionine per ml, washed, and stored as aliquots at 280°C as previously
described (5).
Vero cells were cultured in RPMI 1640 supplemented with 10% NuSerum
(Collaborative Research). 293 human embryonic kidney cells were cultured in a
1:1 mix of Dulbecco modified Eagle medium (DMEM; low glucose; Gibco-BRL,
Bethesda, Md.) and Ham’s F12 medium (Gibco-BRL) supplemented with 10%
fetal bovine serum (FBS). Primary bovine endothelial cells, provided by Judah
Folkman, Catherine Butterfield, and Marsha Moses (13), were grown on gelatin-
coated plastic in DMEM (low glucose; Gibco-BRL) supplemented with 10%
newborn calf serum and 3 ng of basic fibroblastic growth factor (Gibco-BRL) per
ml. EA-Hy926 is a human endothelial cell line that expresses a wide range of
differentiated endothelial cell markers, such as von Willebrand factor antigen,
Weibel-Palade bodies, and factor VIII-related antigen with morphological dis-
tributions similar to those of primary endothelial cells (11, 12). These cells,
provided by Cora-Jean Edgell, were cultured in DMEM (high glucose; Gibco-
BRL) supplemented with 1% hypoxanthine-aminopterin-thymidine (Gibco-
BRL) and 10% FBS. Primary cultures of telencephalic cells, consisting primarily
of astrocytes, with approximately 3% oligodendrocytes and 10% microglia, were
prepared from 1- to 2-day-old Sprague-Dawley rats. This cell preparation re-
sponds to B. burgdorferi by the production of nitric oxide and interleukin-6 and
was prepared as described previously (43). The CATH.a cell line, provided by
Dona Chikaraishi, was derived from a tumor induced in mice by a transgene
targeted to tyrosine hydroxylase-containing neurons and has phenotypic features
of catacholaminergic neurons (41). These cells were grown in RPMI 1640 (Irvine
Scientific) supplemented with 8% horse serum and 4% FBS, fed three times per
week, and split when the monolayer reached 60% confluency. Penicillin (100
U/ml), streptomycin (100 mg/ml), and glutamine (2 mM) were added to all
culture media. 293 cells were cultured in a 7% CO2 atmosphere, and capillary
endothelial cells were cultured in a 10% CO2 atmosphere; all other cells were
cultured in a 5% CO2 atmosphere.
Quantitation of bacterial attachment to mammalian cells. One to two days
prior to each assay, the mammalian cells that were to be tested were lifted and
plated in Nunc 96-well break-apart microtiter plates coated with Yersinia pseudo-
tuberculosis invasin protein, which promotes cell attachment by binding a subset
b1-chain integrins (24). In pilot experiments with primary bovine endothelial
cells, the levels of efficiency of bacterial binding to cells plated on invasin, gelatin,
or invasin plus gelatin were indistinguishable. To assay bacterial attachment to
these cells, frozen aliquots of radiolabeled bacteria were thawed, suspended at
1 3 108 to 2 3 108/ml in MKP-S, and incubated for 2 h at room temperature to
allow for physiologic recovery of the bacteria. The spirochetes were then checked
for intact morphology and vigorous motility and were diluted 1:3 into 10 mM
HEPES–10 mM glucose–50 mM NaCl (pH 7.0) before addition to confluent cell
monolayers that had been washed twice in phosphate-buffered saline (PBS). To
promote host cell-bacterium contact, the microtiter plates were centrifuged at
190 3 g for 5 min at 20°C and then rocked at 20°C for 1 h. Unbound bacteria
were removed by washing the monolayers three times in PBS (150 mM NaCl,
16.9 mM K2HPO4, 4.8 mM KH2PO4 [pH 7.4]) supplemented with 0.2% BSA,
and bound bacteria were quantitated by liquid scintillation.
To test the effect of exogenous proteoglycans or dextran sulfate on bacterial
attachment, bacteria were incubated for 30 min at room temperature in MKP-S
supplemented with chondroitin-4-sulfate, chondroitin-6-sulfate, heparin (por-
cine), dextran sulfate (500 kDa), dermatan sulfate (all purchased from Sigma
Chemical Co., St. Louis, Mo.), or heparan sulfate (generous gift of Bis Lahiri)
and diluted 1:3 into 10 mM HEPES–10 mM glucose–50 mM NaCl, pH 7.0 prior
to infection of monolayers. The proteoglycan-binding chemokine platelet factor
4 (31) (Sigma) was added to bacteria at a final concentration of 5 mg/ml in the
diluted MKP-S just prior to infection of the monolayer. Bound bacteria were
quantitated as described above.
The effect of enzymatic removal of different classes of proteoglycans on bac-
terial attachment was determined as previously described (29). Briefly, mono-
layers were incubated with 35 ml of 0.5 U of heparinase I, heparitinase (hepa-
rinase III), or chondroitinase ABC (all purchased from Sigma) per ml for 2 h at
37°C in RPMI 1640 supplemented with 1% BSA, 1022 trypsin inhibitory units of
aprotinin per ml, and 150 mg of phenylmethylsulfonyl fluoride per ml. The
monolayers were then washed with PBS, incubated with radiolabeled bacteria,
and processed as described above. To test the role of sulfation on bacterial
attachment to proteoglycans, monolayers were cultured overnight in 10% dia-
lyzed FBS (18) in Ham’s F12 medium supplemented with either 30 mM sodium
chlorate, 30 mM sodium chloride, or 30 mM sodium chlorate plus 30 mM sodium
sulfate as described previously (29). Sodium chlorate competitively inhibits pro-
teoglycan sulfation, while the addition of sodium sulfate restores sulfation (1). To
inhibit heparan sulfate and chondroitin sulfate glycosaminoglycan attachment to
the protein core of proteoglycans, cells were cultured overnight in medium
supplemented with 5 mM p-nitrophenyl-b-D-xyloside or, as a control, 5 mM
p-nitrophenyl-a-D-galactoside (26). Monolayers were washed in PBS prior to
infection with bacteria, and bacterial attachment to treated monolayers was
quantitated as described above.
Inhibition of bacterial attachment to purified heparin or dermatan sulfate.
Nunc 96-well break-apart microtiter plates were coated overnight at 4°C with 5
mg of heparin or dermatan sulfate per ml in PBS. To assay bacterial attachment
to these wells, frozen aliquots of radiolabeled bacteria were thawed and sus-
pended at 1 3 108 to 2 3 108/ml in MKP-S as described above. Soluble proteo-
glycan was added to the bacteria at various concentrations, and the mixture was
incubated for 30 min at room temperature. Spirochetes were diluted 1:3 into 10
mM HEPES–10 mM glucose–50 mM NaCl (pH 7.0) before addition to micro-
titer wells. The microtiter plates were centrifuged at 1,430 3 g for 15 min at 20°C
and then rocked at 20°C for 1 h. Unbound bacteria were removed by washing the
wells three times in PBS supplemented with 0.2% BSA, and bound bacteria were
quantitated by liquid scintillation.
RESULTS
Bacterial attachment to Vero and 293 cells is mediated by
different species of glycosaminoglycans. To investigate pro-
teoglycan-mediated attachment of B. burgdorferi to host
cells, Vero cells and 293 cells were infected with the infec-
tious B. burgdorferi strain N40 (clone D10/E9). Patterns of
inhibition of N40 binding to both cell lines by different pro-
teoglycans were remarkably similar: heparin, heparan sulfate,
and dermatan sulfate showed better inhibitory activity than
chondroitin-4-sulfate or chondroitin-6-sulfate (Fig. 1A). As
previously shown (29), Vero cell binding was inhibited by di-
gestion of the monolayer with heparinase, which cleaves hep-
arin-related glycosaminoglycans, or with heparitinase, which
FIG. 1. Attachment of B. burgdorferi to Vero cells is sensitive to heparinase
or heparitinase digestion, while attachment to 293 cells is sensitive to chondroiti-
nase ABC digestion. Bacterial attachment of the infectious B. burgdorferi strain
N40, clone D10/E9, to confluent monolayers was determined as described in
Materials and Methods. (A) Attachment of N40 to Vero cells or 293 cells was
determined (from left to right) in the absence of inhibitor or in the presence of
500 mg of chondroitin-6-sulfate, chondroitin-4-sulfate, heparin, heparan sulfate,
or dermatan sulfate per ml. (B) Bacterial attachment was quantitated (from left
to right) after no treatment or after a 2-h treatment of the monolayers with 0.5
U of heparinase, heparitinase, or chondroitinase ABC per ml.
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cleaves heparan sulfate proteoglycans (Fig. 1B). Chondroiti-
nase ABC, which cleaves chondroitin-4-sulfate, dermatan sul-
fate, and chondroitin-6-sulfate, had no effect on binding to this
cell line. In contrast, parallel digestions with heparinase or
heparitinase had no significant effect on N40 binding to 293
cells, while chondroitinase ABC digestion inhibited attach-
ment by more than 60% (Fig. 1B). These results indicate that
glycosaminoglycans play an important role in recognition of
both cell lines by B. burgdorferi, but that the specific class of
proteoglycans that plays the major role in bacterial attachment
varies with host cell.
Binding of B. burgdorferi to heparan sulfate on endothelial
cells. To determine which, if any, class of glycosaminoglycan
might play a role in bacterial interactions with the endothe-
lium, we investigated bacterial binding to both primary bovine
capillary endothelial cells and to a human endothelial cell line.
Binding of N40 to primary endothelial cells was almost com-
pletely inhibited by heparin or dextran sulfate, partially inhib-
ited by dermatan sulfate, but only minimally inhibited by
chondroitin-4-sulfate or chondroitin-6-sulfate (Fig. 2A, Sol-
uble Inhibitor). Pretreatment of the cells with heparinase or
heparitinase diminished N40 binding by 50%, whereas diges-
tion with chondroitinase ABC had no effect (Fig. 2A, Lyase).
EA-Hy926 is a human endothelial cell line that expresses a
wide range of differentiated endothelial cell markers (11, 12).
N40 attachment to this cell line was inhibited by platelet factor
4, a chemokine that binds to glycosaminoglycans, and by hep-
arin but not by chondroitin-6-sulfate (Fig. 2B, Soluble Inhibi-
tor). Bacterial binding was blocked by pretreatment of EA-
Hy926 cells with b-D-xyloside, which inhibits linkage of the
heparin/heparan sulfate and dermatan/chondroitin sulfate
chains to the protein core of proteoglycans (26). Pretreatment
with a control sugar, a-D-galactoside, had no effect (Fig. 2B,
Inhibitor of Synthesis). Sulfation is apparently required for
attachment of B. burgdorferi to EA-Hy926 cells, because pre-
treatment of EA-Hy926 cells with chlorate, an inhibitor of
proteoglycan sulfation (1), reduced N40 attachment by almost
90% (Fig. 2B, Inhibitor of Sulfation). This effect was specific
for chlorate: chloride treatment had no effect, and the addition
of sulfate along with chlorate partially reversed the inhibition
of binding. Pretreatment of EA-Hy926 cells with heparinase or
heparitinase reduced binding by 90%, while chondroitinase
ABC treatment had little effect (Fig. 2B, Lyase). Taken to-
gether with the analysis of primary endothelial cells, these
experiments provide evidence that proteoglycans are critical in
the attachment of B. burgdorferi to endothelial cells and that
heparin/heparan sulfate in particular play an important role in
this recognition process. In contrast, there was no evidence
that chondroitin or dermatan sulfate proteoglycans were re-
quired for efficient bacterial binding to endothelial cells.
B. burgdorferi binding to heparinase- and chondroitinase-
sensitive proteoglycans expressed by cultured brain cells. To
investigate the interaction of B. burgdorferi with a second po-
tential target tissue, a glial cell-enriched population of primary
mixed telencephalic brain cells was cultured from neonatal rats
(43). Heparin, dextran sulfate, and platelet factor 4 reduced
N40 binding, as did inhibition of sulfation by pretreatment with
chlorate (Fig. 3A). Digestion of cultured telencephalic cells
with heparinase or heparitinase diminished bacterial attach-
ment by about 60% (Fig. 3A, Lyase), indicating that heparan
sulfate proteoglycans expressed by telencephalic cells contrib-
ute to bacterial binding, as was the case for binding to endo-
thelial cells. In contrast to the results with endothelial cells
however, chondroitinase ABC digestion of telencephalic cells
inhibited N40 attachment by about 45%. These results suggest
that for this population of neural cells, chondroitinase-sensi-
tive as well as heparinase-sensitive proteoglycans contribute to
bacterial recognition.
To determine which species of proteoglycans contribute to
B. burgdorferi attachment to neuronal cells, we assayed the
effect of lyase digestion on bacterial binding to the cata-
cholaminergic neuron-derived CATH.a cells (41). Heparinase,
heparitinase, and chondroitinase ABC digestion of CATH.a
cells each resulted in a significant inhibition of N40 attachment
(Fig. 3B), indicating that a chondroitinase-sensitive component
of CATH.a cells promotes attachment of B. burgdorferi. Lyase
digestion of the pheochromocytoma cell line, PC12, gave sim-
ilar results (data not shown). Thus, in this sampling of two
neuronal cell lines and central nervous system-derived primary
FIG. 2. Heparin/heparan sulfate proteoglycans contribute to binding of B. burgdorferi to endothelial cells. Bacterial attachment by the infectious B. burgdorferi strain
N40 to endothelial cell monolayers was determined as described in Materials and Methods. “No cells” denotes attachment to wells without cells; “No inhibitor” denotes
binding to endothelial cells in the absence of inhibitor. Inhibitors tested included chondroitin-6-sulfate (Chon-6-SO4), chondroitin-4-sulfate (Chon-4-SO4), heparin,
dextran sulfate (Dex-SO4), dermatan sulfate (Derm-SO4), and platelet factor 4 (Plt. Fact. 4). “Lyase” indicates the degree of binding after a 2-h incubation with 0.5
U of heparinase, heparitinase, or chondroitinase ABC (Chon. ABC) per ml. (A) Bacterial attachment to primary capillary endothelial cells. Inhibitors were tested at
a concentration of 20 mg/ml. (B) Bacterial attachment to EA-Hy926, an endothelial cell line. Chondroitin-6-sulfate and heparin were tested at a concentration of 10
mg/ml, and platelet factor 4 was tested at 5 mg/ml. “Inhibitor of Synthesis” denotes binding to cells treated overnight with p-nitrophenyl-b-D-xyloside, an inhibitor of
glycosaminoglycan attachment to the protein core (26), or treatment with the control sugar, p-nitrophenyl-a-D-galactoside, each at 5 mM. “Sulfation Inhibitor” indicates
treatment with chlorate, an inhibitor of host cell sulfation of proteoglycans (1). Monolayers were cultured overnight in medium supplemented with either 30 mM sodium
chlorate, 30 mM sodium chloride, or 30 mM sodium chlorate plus 30 mM sodium sulfate.
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neurons and glia, chondroitinase ABC-sensitive proteoglycans
contributed to B. burgdorferi attachment.
Dermatan sulfate inhibits bacterial binding to immobilized
heparin, and heparin inhibits binding to immobilized derma-
tan sulfate. The analysis of lyase-treated Vero and 293 cells
(Fig. 1B) is consistent with the suggestion that heparin/hepa-
ran sulfate mediates B. burgdorferi attachment to Vero cells,
while a chondroitinase ABC-sensitive glycosaminoglycan, e.g.,
dermatan sulfate, mediates attachment to 293 cells. The ob-
served cell-specific difference in the species of glycosaminogly-
cans recognized by B. burgdorferi could be due to the expres-
sion of a single glycosaminoglycan-binding molecule that
recognizes both heparan sulfate and dermatan sulfate. Alter-
natively, the spirochete could utilize two independent mecha-
nisms, one recognizing heparin/heparan sulfate and the other
recognizing dermatan sulfate. In the latter case, one might
expect that Vero cell binding would be inhibited most effi-
ciently by heparin, whereas dermatan sulfate would be the
more effective inhibitor of attachment to 293 cells. Heparin,
dermatan sulfate, and chondroitin-6-sulfate were titrated as
inhibitors of strain N40 binding to Vero or 293 cells. Both
heparin and dermatan sulfate blocked binding to both cell
lines, and regardless of cell line, heparin was the best inhibitor
of N40 attachment, with a 50% inhibitory concentration (IC50)
4- to 45-fold lower than that for dermatan sulfate (Table 1).
Because intact mammalian cells present a complex mixture
of potential receptors for B. burgdorferi, we also determined
whether bacterial binding to immobilized heparin could be
inhibited by dermatan sulfate and, conversely, whether binding
to immobilized dermatan sulfate could be inhibited by heparin.
Each proteoglycan inhibited binding of B. burgdorferi N40 to
the other (Fig. 4). Heparin was the more potent inhibitor
regardless of which glycosaminoglycan was immobilized, with
an IC50 three- to sixfold lower than that for dermatan sulfate
(Table 1). Chondroitin-6-sulfate showed some inhibitory activ-
ity but was the poorest inhibitor of the three tested. That
heparin was the most potent inhibitor of B. burgdorferi N40
attachment to purified heparin, dermatan sulfate, Vero cells,
or 293 cells is consistent with the hypothesis that a single
glycosaminoglycan-binding pathway recognizes multiple spe-
cies of glycosaminoglycans.
DISCUSSION
Given that endothelial damage is one of the hallmarks of
Lyme disease (2, 10) and that neurologic manifestations are a
prominent feature of this illness (30), it is likely that the inter-
actions of B. burgdorferi with endothelial cells and cells in the
nervous system play an important role in vivo. We analyzed
bacterial attachment to primary endothelial cells, primary cen-
tral nervous system-derived glial cells, and cell lines of endo-
thelial or neural origin and found that binding of B. burgdorferi
to all of these cells was mediated by proteoglycans. Binding to
all cells tested was inhibited by the addition of heparin, hepa-
ran sulfate, or dermatan sulfate and by platelet factor 4, a
chemokine that binds glycosaminoglycans. In addition, cell at-
tachment was diminished by pretreatment of these cells with
an inhibitor of proteoglycan synthesis (b-D-xyloside) or sulfa-
tion (sodium chlorate) or by digestion of cell surface glycos-
aminoglycans with lyases. Given the widespread expression of
proteoglycans, it is likely that proteoglycan binding by the
spirochete contributes to the recognition of other cell types as
well.
Although glycosaminoglycans mediate attachment to many
cell types, removal of specific classes of glycosaminoglycans
with lyases indicated that the particular populations of glycos-
aminoglycans that contribute to spirochetal attachment vary
with cell type. Heparin/heparan sulfate appeared to play the
most critical role for spirochetal binding to primary endothelial
FIG. 3. Attachment of B. burgdorferi to neural cells is mediated by both heparinase- and chondroitinase ABC-sensitive proteoglycans. Attachment of N40 to primary
rat telencephalic cells (43) (A) or the mouse midbrain neuronal cell line CATH.a (41) (B) was assessed in assays using exogenous proteoglycans, platelet factor 4,
chlorate inhibition of proteoglycan sulfation, or lyase digestion of glycosaminoglycans as described in the legend to Fig. 1.
TABLE 1. Comparison of heparin and dermatan sulfate as
inhibitors of bacterial attachment to immobilized
proteoglycans or mammalian cells
Inhibitor
IC50 (mg/ml)a
Vero cells 293 cells Heparin Dermatan sulfate
Heparin 8.0 1.3 0.2 0.5
Dermatan sulfate 32 60 0.6 3.2
Chondroitin-6-sulfate .500 .500 .500 18
a Bacterial attachment of radiolabeled B. burgdorferi N40 to mammalian cells
or immobilized proteoglycans was determined in the presence of various con-
centrations of heparin, dermatan sulfate, or chondroitin-6-sulfate (see Materials
and Methods). At the concentration of inhibitor indicated, bacterial attachment
was 50% of the level of binding in the absence of inhibitor (Fig. 4).
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cells, the EA-Hy926 endothelial cell line, and Vero cells. A
chondroitinase ABC-sensitive glycosaminoglycan, presumably
dermatan sulfate, mediated attachment to 293 cells. Binding
to primary telencephalon cells and two neuronal cell lines
appeared to be mediated by both heparin/heparan sulfate
and dermatan sulfate. It was previously shown that binding
of B. burgdorferi 297 to HeLa cells was inhibited by digestion
with either heparinase or chondroitinase ABC (23). Of the
glycosaminoglycans that are substrates for chondroitinase
ABC (chondroitin-4-sulfate, chondroitin-6-sulfate, and derma-
tan sulfate), only dermatan sulfate is a potent inhibitor of
bacterial attachment to mammalian cells. Thus, it is likely that
the chondroitinase ABC-sensitive glycosaminoglycan that is
critical for B. burgdorferi recognition is dermatan sulfate. Con-
sistent with this hypothesis, chondroitinase AC, which does not
cleave dermatan sulfate, had no effect on B. burgdorferi attach-
ment to HeLa cells (23).
At the present time, we do not know whether the relative
importance of a given species of glycosaminoglycan in bacterial
binding to a particular cell type reflects its relative affinity for
the bacterium, its abundance on the cell surface, or both.
Heparan sulfate and chondroitin sulfate are expressed to a
variable extent on virtually all cells, while dermatan sulfate is
less common (27). Although dermatan sulfate did not appear
to participate in bacterial binding to endothelial cells in this
study, cultured bovine aortic endothelial cells have been shown
to express this glycosaminoglycan (35). Dermatan sulfate ap-
peared to promote bacterial attachment to cultured rat brain
cells, even though it is apparently poorly expressed in rat brain
(21, 33). It is difficult, however, to directly compare these
previous studies to our results, because proteoglycan expres-
sion can vary considerably with culture conditions. For this
reason, multiple representatives of both endothelial and neural
cells were evaluated in this study.
The recognition of multiple classes of proteoglycans by
B. burgdorferi could reflect the expression of several proteogly-
can receptors, or the expression of a single receptor that rec-
ognizes different species of glycosaminoglycans. We found no
evidence for independent mechanisms for binding dermatan
sulfate and heparin by strain N40: heparin was a better inhib-
itor than dermatan sulfate, regardless of whether the substrate
was heparin, dermatan sulfate, Vero cells, or 293 cells. Previ-
ous results demonstrating that 100 mg of heparan sulfate or
dermatan sulfate per ml partially (46 or 59%, respectively)
inhibits heparin binding by B. burgdorferi also suggest a pro-
miscuous glycosaminoglycan-binding pathway that binds hep-
arin with the highest affinity (23). It is not uncommon for
glycosaminoglycan-binding receptors to recognize multiple
species of glycosaminoglycans, because the polyanionic nature
of these molecules is a critical determinant in these interac-
tions (27).
Although our results are consistent with a single proteogly-
can-binding mechanism, we cannot rule out the possibility that
binding of one proteoglycan to the surface of the spirochete
can inhibit attachment to other molecules nonspecifically, e.g.,
by steric hindrance, or by conferring a strong negative charge
to the bacterial surface. Guo et al. showed that binding of
B. burgdorferi B31 to decorin, a dermatan sulfate/chondroitin
sulfate proteoglycan, was not inhibited by 10 mg of heparin per
ml, whereas the same concentration of exogenous decorin
blocked binding (19). This finding could indicate that the
decorin binding and heparin binding are mediated by different
bacterial molecules. Alternatively, the specificity of proteogly-
can binding varies somewhat among strains of Lyme disease
spirochete (35a), and strain B31 may express a proteoglycan-
binding receptor that binds to decorin with much higher affinity
than it does to heparin. Resolution of the question of one
versus multiple proteoglycan-binding pathways awaits further
characterization of the bacterial molecules that mediate the
varied interactions that have been described to date.
While it is clear that proteoglycan recognition promotes
bacterial attachment to a wide variety of cells, these results do
not preclude the involvement of other host molecules, and the
degree of residual binding upon inhibition of the proteoglycan
pathway may reflect the activity of additional binding path-
ways. For example, integrins contribute to bacterial attachment
to platelets (5) and other cell types (6), while galactocerebro-
side promotes binding to Schwann cells (17). Glycosaminogly-
cans often act in concert with other cell surface receptors to
promote ligand binding (22, 38, 45), and attachment to pro-
teoglycans by the Lyme disease spirochete could facilitate
binding to other classes of molecules. The precise sequence of
events that occur during bacterial attachment to host cells, as
well as the way in which this interaction may promote coloni-
zation of specific tissues, will be the subject of future investi-
gations.
FIG. 4. Inhibition of bacterial attachment to dermatan sulfate by heparin and to heparin by dermatan sulfate. Bacterial attachment of B. burgdorferi N40 to
immobilized heparin or dermatan sulfate was determined in the presence of various concentrations of exogenous proteoglycan. Binding is expressed relative to the level
of binding in the absence of inhibitor. (A) B. burgdorferi N40 attachment to immobilized heparin sulfate; (B) N40 attachment to immobilized dermatan sulfate.
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